ReNeuron gained 51p (30%) to 222p on Tuesday after it granted a Fosun subsidiary exclusive rights to develop and commercialize its hRPC and CTX stem cell therapies in China. ReNeuron Group plc will receive $7.9 million up front and is eligible for estimated milestones of $104.8 million, plus 12-14% tiered royalties. Source: Biocentury 9/4/2019